APGE
Apogee Therapeutics, Inc.74.78
-2.03-2.64%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
5.11BP/E (TTM)
-Basic EPS (TTM)
-4.38Dividend Yield
0%Recent Filings
8-K
Apogee raises $323M in offering
Apogee Therapeutics priced a public offering on October 8, 2025, selling 6,951,221 common shares at $41.00 each and pre-funded warrants for 365,853 shares, with underwriters exercising their full option for 1,097,561 more shares, netting approximately $323.3 million after expenses. The funds will support clinical development of APG777. Enrollment in the APEX Phase 2 atopic dermatitis trial expanded to 320 patients, with topline data now due in Q1 2026 for maintenance and Q2 2026 for induction. Clinical timelines advanced.
8-K
APG777 Phase 2 success
Apogee Therapeutics unveiled positive 16-week Phase 2 APEX Part A data for APG777, hitting primary and key secondary endpoints with a 71.0% EASI reduction versus 33.8% for placebo in moderate-to-severe atopic dermatitis. This underscores APG777's edge with potential 3- or 6-month dosing, slashing injections to 2-4 yearly from 26 under standard care. Cash at $621.2 million funds operations into Q1 2028, while R&D expenses jumped to $55.7 million amid pipeline acceleration. Part B readout speeds to mid-2026.
10-Q
Q2 FY2025 results
Apogee Therapeutics ramped up R&D spending in Q2 FY2025 ended June 30, 2025, with expenses climbing 68% y/y to $55.7M on APG777 Phase 2 trial initiation and manufacturing scale-up, driving a $73.2M operating loss—up from $44.1M last year—while net loss widened to $66.1M after $7.1M interest income. YTD, R&D hit $102.1M (65% y/y rise) and net loss reached $121.4M, or $2.08 diluted EPS on 58.3M shares, matching calculations with no anti-dilution. Cash burn accelerated to $110.5M from operations, offset by $91.1M investing inflows, leaving $124.2M in cash equivalents and $497.0M in marketable securities for runway through mid-2026. No debt burdens the balance sheet. Clinical momentum builds, yet regulatory hurdles loom large.
8-K
APG777 Phase 2 data excels
Apogee Therapeutics unveiled positive 16-week data from Part A of its Phase 2 APEX trial, where APG777 achieved a 71.0% EASI reduction versus 33.8% for placebo, meeting the primary endpoint and delivering the highest EASI-75 response (66.9%, 42.5% placebo-adjusted) among biologics in global studies. The drug showed rapid itch relief, lesion reduction, and a favorable safety profile with no injection site reactions, while testing 3- or 6-month maintenance dosing. Part B readout accelerates to mid-2026 for higher exposures; first patient dosed in APG279 head-to-head trial versus DUPIXENT, readout in H2 2026. APG777 advances toward Phase 3 in 2026.
8-K
Apogee's annual meeting results
Apogee Therapeutics held its 2025 Annual Meeting on June 17, electing Lisa Bollinger, Tomas Kiselak, and Nimish Shah as Class II directors to serve until 2028, with strong support for Kiselak but notable abstentions for the others. Shareholders ratified Ernst & Young as auditors for the year ending December 31, 2025, and voted overwhelmingly for annual advisory votes on executive compensation. This alignment signals steady governance amid biotech volatility.
IPO
Employees
Sector
Industry
ADPT
Adaptive Biotechnologies Corpor
15.93+0.24
ALDX
Aldeyra Therapeutics, Inc.
5.31+1.32
APLM
Apollomics Inc.
17.02+0.92
APLS
Apellis Pharmaceuticals, Inc.
25.31+0.75
APLT
Applied Therapeutics, Inc.
0.12+0.00
APRE
Aprea Therapeutics, Inc.
0.91-0.01
APVO
Aptevo Therapeutics Inc.
1.10+0.06
ATXS
Astria Therapeutics, Inc.
12.87-0.05
COEP
Coeptis Therapeutics Holdings,
14.43-0.66
QTTB
Q32 Bio Inc.
2.88-0.17